Faible taux de succès du sevrage tabagique à court et moyen termes au décours d’un infarctus aigu du myocarde dans un service de cardiologie de Dakar au Sénégal

Introduction:Le tabagisme est un puissant facteur de risque cardio-vasculaire. Son sevrage semble moins bien pris en compte chez les coronariens. Les objectifs de ce travail étaient d’évaluer la prévalence du tabagisme et le sevrage tabagique au décours d’un infarctus du myocarde dans un service de cardiologie au Sénégal. Méthodes: Il s’agit d’une étude transversale et descriptive réalisée entre janvier 2008 et juin 2010. Nous avons recruté les patients hospitalisés pour infarctus du myocarde puis les fumeurs actifs ont été inclus dans notre enquête. Les malades étaient sensibilisés pour l’arrêt du tabac puis suivis à 3 mois, 6 mois et 12 mois pour évaluer le sevrage tabagique. Résultats: Nous avons recensé 82 patients hospitalisés pour un infarctus du myocarde, parmi eux 26 sujets (25 hommes) étaient fumeurs (31,7%). L’âge moyen des sujets fumeurs était de 56 ± 11,5 ans. La consommation moyenne de tabac était de 32 ± 14 paquets-année et le score moyen de Fagerström de 8. Tous les patients ont arrêté le tabac pendant l’hospitalisation. Après un suivi de 3 mois, 45% des patients ont repris le tabac, 65% à 6 mois et 85% à 12 mois. Conclusion: Le tabagisme est assez fréquent chez les patients sénégalais présentant un infarctus du myocarde. Le taux de sevrage tabagique à court et moyen termes est faible. Le sevrage tabagique devrait alors constituer un objectif privilégié dans la prévention des maladies cardio-vasculaires.Key words: Tabagisme, sevrage, coronaropathie, risque cardio-vasculaire, Senega

Epilespie de l’enfant et de l’adolescent au Senegal

Introduction L’épilepsie constitue un problème de santé publique au Sénégal avec une prévalence de 8,3 à 14/1000. Elle concerne principalement les enfants. L’objectif de ce travail est d’étudier les aspects biographiques, phénotypiques et évolutifs de la maladie épileptique dans une cohorte d’enfants au Sénégal.Méthodologie Il s’agit d’une étude rétrospective de dossiers d’enfants épileptiques suivis régulièrement au CHU de FANN et à l’Hôpital d’Enfants Albert Royer, de Juillet 2003 à décembre 2010. Les critères d’inclusion étaient: épileptiques âgés de moins de 18 ans, régulièrement suivis depuis au moins 3 ans, ayant un traitement adapté, à dose efficace, avec une bonne observance thérapeutique.Résultats Nous avons colligé 522 enfants, âgés de 3 mois à 16 ans, avec un sex-ratio de 1,7 en faveur des garçons. L’épilepsie était idiopathique chez 57% des enfants et non idiopathique chez 43% des patients. Les facteurs étiologiques étaient dominés par la consanguinité parentale, les anomalies de la grossesse et de l’accouchement, les infections du système nerveux central. Dans le groupe des épilepsies idiopathiques la consanguinité parentale et l’épilepsie familiale étaient retrouvées respectivement chez 64 enfants (21,62%) et 20 enfants (6,75%). Neuf enfants (3%) présentaient un trouble du langage isolé, alors qu’un seul enfant (0,33%) avait un déficit cognitif global. Dans le groupe des épilepsies non idiopathiques, les signes associés à l’épilepsie étaient les troubles du langage (15,70%), du comportement (15%) et des déficits moteurs (10,32%). 22,41% des enfants scolarisés avaient des difficultés d’apprentissage menant parfois à des redoublements scolaires ou une exclusion.Conclusion La classification syndromique à l’épilepsie est nécessaire pour une bonne prévision pronostique et thérapeutique. Le caractère idiopathique ou non en est pour une grande place, corrélé le plus souvent à une épilepsie familial ou une consanguinité ou affection périnatal ou infectieuse du système nerveux central.Mots clés : Epilepsie, syndrome épileptique, Sénégal

Genetic Characterization of Human T-Cell Lymphotropic Virus Type 1 in Mozambique: Transcontinental Lineages Drive the HTLV-1 Endemic

Human T-cell lymphotropic virus type 1 (HTLV-1) is the causative agent of Adult T-Cell Leukemia/Lymphoma (ATL), the Tropical Spastic Paraparesis/HTLV-1-associated Myelopathy (TSP/HAM) and other inflammatory diseases, including dermatitis, uveitis, and myositis. It is estimated that 2–8% of the infected persons will develop a HTLV-1-associated disease during their lifetimes, frequently TSP/HAM. Thus far, there is not a specific treatment to this progressive and chronic disease. HTLV-1 has means of three transmission: (i) from mother to child during prolonged breastfeeding, (ii) between sexual partners and (iii) through blood transfusion. HTLV-1 has been characterized in 7 subtypes and the geographical distribution and the clinical impact of this infection is not well known, mainly in African population. HTLV-1 is endemic in sub-Saharan Africa. Mozambique is a country of southeastern Africa where TSP/HAM cases were reported. Recently, our group estimated the HTLV prevalence among Mozambican blood donors as 0.9%. In this work we performed a genetic analysis of HTLV-1 in blood donors and HIV/HTLV co-infected patients from Maputo, Mozambique. Our results showed the presence of three HTLV-1 clusters within the Cosmopolitan/Transcontinental subtype/subgroup. The differential rates of HIV-1/HTLV-1 co-infection in the three HTLV-1 clusters demonstrated the dynamic of the two viruses and the need for implementation of control measures focusing on both retroviruses

Molecular Epidemiology of Endemic Human T-Lymphotropic Virus Type 1 in a Rural Community in Guinea-Bissau

Human T-Lymphotropic Virus type 1 (HTLV-1) affects millions of people worldwide. It is very similar to Simian T-Lymphotropic Virus, a virus that circulates in monkeys. HTLV-1 causes a lethal form of leukemia (Adult T-cell Leukemia) and a debilitating neurological syndrome (HTLV-associated myelopathy/tropical spastic paraparesis) in approximately 5% of infected people. Based on sequence variation, HTLV-1 can be divided into 7 subtypes (1a–1g) with the Cosmopolitan subtype 1a further subdivided into subgroups (A–E). We examined HTLV-1 diversity in a rural area in Guinea-Bissau, a country in West Africa with a high HTLV-1 prevalence (5%). We found that most viruses belong to the Cosmopolitan subtype 1a, subgroup D, but 2 viruses belonged to subtype 1g. This subtype had thus far only been found in monkey hunters in Cameroon, who were probably recently infected by monkeys. Our findings indicate that this subtype has spread beyond Central Africa. An important, unresolved question is whether persons with this subtype were infected by monkeys or through human-to-human transmission

The future of African nowcasting

Nowcasting (weather forecasting predictions from zero to several hours) has enormous value and potential in Africa, where populations and economic activity are highly vulnerable to rapidly changing weather conditions. Timely issuing of warnings, a few hours before an event, can enable the public and decision-makers to take action. Rainfall radar estimates are not widely available in Africa, nor likely to be in the coming years, and numerical weather prediction (NWP) currently has low skill over the African continent. Therefore, for the delivery of nowcasting in Africa, satellite products are the best practical option and needed urgently (Roberts et al., 2021). Fifteen minute (or faster) updates of MSG (Meteosat Second Generation) images and NWC-SAF (Nowcasting Satellite Applications Facility) products are crucial for nowcasting to warn users (e.g. fisherfolk on Lake Victoria, flooding in urban areas, etc.) on pending severe storms. The possibility to have such products every 10 minutes, as well as data from the forthcoming MTG (Meteosat Third Generation) lightning imager, would be highly beneficial to all African countries, saving lives and livelihoods where high population growth and the most extreme impacts of climate change combine

Primate TNF Promoters Reveal Markers of Phylogeny and Evolution of Innate Immunity

Background. Tumor necrosis factor (TNF) is a critical cytokine in the immune response whose transcriptional activation is controlled by a proximal promoter region that is highly conserved in mammals and, in particular, primates. Specific single nucleotide polymorphisms (SNPs) upstream of the proximal human TNF promoter have been identified, which are markers of human ancestry. Methodology/Principal findings. Using a comparative genomics approach we show that certain fixed genetic differences in the TNF promoter serve as markers of primate speciation. We also demonstrate that distinct alleles of most human TNF promoter SNPs are identical to fixed nucleotides in primate TNF promoters. Furthermore, we identify fixed genetic differences within the proximal TNF promoters of Asian apes that do not occur in African ape or human TNF promoters. Strikingly, protein-DNA binding assays and gene reporter assays comparing these Asian ape TNF promoters to African ape and human TNF promoters demonstrate that, unlike the fixed differences that we define that are associated with primate phylogeny, these Asian ape-specific fixed differences impair transcription factor binding at an Sp1 site and decrease TNF transcription induced by bacterial stimulation of macrophages. Conclusions/significance. Here, we have presented the broadest interspecies comparison of a regulatory region of an innate immune response gene to date. We have characterized nucleotide positions in Asian ape TNF promoters that underlie functional changes in cell type- and stimulus-specific activation of the TNF gene. We have also identified ancestral TNF promoter nucleotide states in the primate lineage that correspond to human SNP alleles. These findings may reflect evolution of Asian and African apes under a distinct set of infectious disease pressures involving the innate immune response and TNF

SIVagm Infection in Wild African Green Monkeys from South Africa: Epidemiology, Natural History, and Evolutionary Considerations

Pathogenesis studies of SIV infection have not been performed to date in wild monkeys due to difficulty in collecting and storing samples on site and the lack of analytical reagents covering the extensive SIV diversity. We performed a large scale study of molecular epidemiology and natural history of SIVagm infection in 225 free-ranging AGMs from multiple locations in South Africa. SIV prevalence (established by sequencing pol, env, and gag) varied dramatically between infant/juvenile (7%) and adult animals (68%) (p<0.0001), and between adult females (78%) and males (57%). Phylogenetic analyses revealed an extensive genetic diversity, including frequent recombination events. Some AGMs harbored epidemiologically linked viruses. Viruses infecting AGMs in the Free State, which are separated from those on the coastal side by the Drakensberg Mountains, formed a separate cluster in the phylogenetic trees; this observation supports a long standing presence of SIV in AGMs, at least from the time of their speciation to their Plio-Pleistocene migration. Specific primers/probes were synthesized based on the pol sequence data and viral loads (VLs) were quantified. VLs were of 104-106 RNA copies/ml, in the range of those observed in experimentally-infected monkeys, validating the experimental approaches in natural hosts. VLs were significantly higher (107-108 RNA copies/ml) in 10 AGMs diagnosed as acutely infected based on SIV seronegativity (Fiebig II), which suggests a very active transmission of SIVagm in the wild. Neither cytokine levels (as biomarkers of immune activation) nor sCD14 levels (a biomarker of microbial translocation) were different between SIV-infected and SIV-uninfected monkeys. This complex algorithm combining sequencing and phylogeny, VL quantification, serology, and testing of surrogate markers of microbial translocation and immune activation permits a systematic investigation of the epidemiology, viral diversity and natural history of SIV infection in wild African natural hosts. © 2013 Ma et al

Innate immunity against HIV: a priority target for HIV prevention research

This review summarizes recent advances and current gaps in understanding of innate immunity to human immunodeficiency virus (HIV) infection, and identifies key scientific priorities to enable application of this knowledge to the development of novel prevention strategies (vaccines and microbicides). It builds on productive discussion and new data arising out of a workshop on innate immunity against HIV held at the European Commission in Brussels, together with recent observations from the literature